Abstract
Behavior analysts often work as part of an interdisciplinary team, and different team members may prescribe different interventions for a single client. One such intervention that is commonly encountered is a change in medication. Changes in medication regimens have the potential to alter behavior in a number of ways. As such, it is important for all team members to be aware of every intervention and to consider how different interventions may interact with each other. These facts make regular and clear communication among team members vital for treatment success. While working as part of an interdisciplinary team, behavior analysts must abide by their ethics code, which sometimes means advocating for their client with the rest of the team. This article will review some possible implications of medicinal interventions, potential ethical issues that can arise, and a case study from the authors’ experience. Finally, the authors propose a decision-making tree that can aid in determining the best course of action when a team member proposes an intervention in addition to, or concurrent with, interventions proposed by the behavior analyst.
Similar content being viewed by others
References
American Medical Association. (2007). Code of medical ethics. Chicago, IL: American Medical Association.
American Psychiatric Association. (2001). The principles of medical ethics: with annotations especially applicable to psychiatry. Washington, D.C.: American Psychiatric Association.
American Psychological Association. (2007). Code of medical ethics. Chicago, IL: American Medical Association.
Bailey, J. S., & Pyles, D. A. M. (1989). Behavior diagnostics. In E. Cipani (Ed.), The treatment of severe behavior disorders: behavior analysis approaches (pp. 85–107). Washington, DC, US: American Association on Mental Retardation.
Behavior Analyst Certification Board. (2014). Professional and ethical compliance code for behavior analysts. Littleton, CO: Behavior Analyst Certification Board, ® Inc.
Brodhead, M. (2015). Maintaining professional relationships in an interdisciplinary setting: strategies for navigating nonbehavioral treatment recommendations for individuals with autism. Behavior Analysis in Practice, 8, 70–78. doi:10.1007/s40617-015-0042-7.
Crosland, K. A., Zarcone, J. R., Lindauer, S. E., Valdovinos, M. G., Zarcone, T. J., Hellings, J. A., & Schroeder, S. R. (2003). Use of functional analysis methodology in the evaluation of medication effects. Journal of Autism and Developmental Disorders, 33(3), 271–279.
Dawson, G., Jones, E. H. J., Merkle, K., Venema, K., Lowy, R., Faja, S., Kamara, D., Murias, M., Greenson, J., Winter, J., Smith, M., Rogers, S. J., & Webb, S. J. (2012). Early behavioral intervention is associated with normalized brain activity in young children with autism. Journal of the American Academy of Child & Adolescent Psychiatry, 51(11), 1150–1159.
Dawson, G., Rogers, S., Munson, J., Smith, M., Winter, J., Greenson, J., Donaldson, A., & Varley, J. (2010). Randomized, controlled trial of an intervention for toddlers with autism: the Early Start Denver Model. Pediatrics, 125(1), e17–e23.
Eikeseth, S., Smith, T., Jahr, E., & Eldevik, S. (2007). Outcome for children with autism who began intensive behavioral treatment between ages 4 and 7: a comparison controlled study. Behavior Modification, 31(3), 264–278.
Fisher, W., Piazza, C., & Page, T. (1989). Assessing independent and interactive effects of behavioral and pharmacological interventions for a client with dual diagnoses. Journal of Behavior Therapy and Experimental Psychology., 20(3), 241–250.
Garcia, A. B., Sapyta, J. J., Moore, P. S., Freeman, J. B., Franklin, M. E., March, J. S., & Foa, E. B. (2010). Predictors and moderators of treatment outcome in the Pediatric Obsessive Compulsive Treatment Study (POTS I). Journal of the American Academy of Child & Adolescent Psychiatry, 49(10), 1024–1033.
Hoza, B., Pelham, W. E., Sams, S. E., & Carlson, C. (1992). An examination of the dosage effects of both behavior therapy and methylphenidate on the classroom performance of two ADHD children. Behavior Modification., 16(2), 164–192.
LaRue, R. H., Northup, J., Baumeister, A. A., Hawkins, M. F., Seale, L., Williams, T., & Ridgway, A. (2008). An evaluation of stimulant medication on the reinforcing effects of play. Journal of Applied Behavior Analysis, 41, 143–147.
McPheeters, M. L., Warren, Z., Sathe, N., Bruzek, J. L., Krishnaswami, S., Jerome, R. N., & Veenstra-VanderWeele, J. (2011). A systematic review of medical treatments for children with autism spectrum disorders. Pediatrics, 127(5), e1312–e1321.
MTA Cooperative Group. (1999). A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Archives of General Psychiatry, 56, 1073–1086.
Murray, D. W., Arnold, L. E., Swanson, J., Wells, K., Burns, K., Jensen, P., Hechtman, L., Paykina, N., Legato, L., & Strauss, T. (2008). A clinical review of outcomes of the Multimodal Treatment Study of Children with Attention-Deficit/Hyperactivity Disorder (MTA). Current Psychiatry Reports, 10, 424–431.
O’Neill, R. E., Horner, R. H., Albin, R. W., Sprague, J., Storey, R., Newton, K., & J. S. (1996). Functional assessment and program development for problem behavior: a practical handbook (2nd ed.). Pacific Grove, CA: Brooks/Cole.
Northup, J., Fusilier, I., Swanson, V., Roane, H., & Borrero, J. (1997). An evaluation of methylphenidate as a potential establishing operation for some common classroom reinforcers. Journal of Applied Behavior Analysis, 30, 615–625.
Piacentini, J., Bennet, S., Compton, S. N., Kendall, P. C., Birmaher, B., Albano, A. M., March, J., Sherrill, J., Sakolsky, D., Ginsburg, G., Rynn, M., Bergman, R. L., Gosch, E., Waslick, B., Iyengar, S., McCracken, J., & Walkup, J. (2014). 24- and 36-week outcomes for the Child/Adolescent Anxiety Multimodal Study (CAMS). Journal of the American Academy of Child & Adolescent Psychiatry, 53(3), 297–310.
Schall, C. (2002). A consumer’s guide to monitoring psychotropic medication for individuals with autism spectrum disorders. Focus on autism and other developmental disabilities, 17(4), 229–235.
TADS Team. (2004). Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents with Depression Study (TADS) randomized controlled trial. Journal of the American Medical Association, 292(7), 807–820.
Valdovinos, M. G., & Kennedy, C. H. (2004). A behavior-analytic conceptualization of the side effects of psychotropic medications. The Behavior Analyst, 27, 231–238.
Valdovinos, M. G., Nelson, S. M., Kuhle, J. L., & Dierks, A. M. (2009). Using analogue functional analysis to measure variations in problem behavior rate and function after psychotropic medication changes: a clinical demonstration. Journal of Mental Health Research in Intellectual Disabilities, 2, 279–293.
Vinokur-Kaplan, D. (1995). Enhancing the effectiveness of interdisciplinary mental health treatment teams. Administration and Policy in Mental Health, 22(5), 521–530.
Walkup, J. T., Albano, A. M., Piacentini, J., Birmaher, B., Compton, S. N., Sherrill, J. T., Ginsburg, G. S., Rynn, M. A., McCracken, J., Waslick, B., Iyengar, S., March, J. S., & Kendall, P. C. (2008). Cognitive behavioral therapy, sertraline, or a combination in childhood anxiety. The New England Journal of Medicine, 359(26), 2753–2766.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
The authors declare that they have no conflict of interest.
Appendix
Appendix
Included here is a general set of questions that can be tailored for each client as necessary. This list in not exhaustive, and behavior analysts should take care to individualize for each client.
-
How did the client sleep last night?
-
How is the client eating, any changes in diet?
-
Any changes in activity level?
-
Any changes in other treatments or services (e.g., medications, therapeutic services)?
-
Has the client shown any symptoms of illness or injury?
-
Are there any new behaviors of concern?
-
Have any existing target behaviors occurred in situations different than typical?
-
Have there been any schedule/routine changes (e.g., toileting, hygiene/cleanliness, school changes)?
-
Have there been any changes in living conditions (house rules, roommates)?
-
Have there been any unusual stressors (e.g., death in family, parent separation, residential move, staffing/provider changes, probe in more detail based on client history and response)?
Rights and permissions
About this article
Cite this article
Newhouse-Oisten, M.K., Peck, K.M., Conway, A.A. et al. Ethical Considerations for Interdisciplinary Collaboration with Prescribing Professionals. Behav Analysis Practice 10, 145–153 (2017). https://doi.org/10.1007/s40617-017-0184-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40617-017-0184-x